For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
Scope of the Report:
The global average gross margin of BCG Vaccine is in an decreasing trend, from 71.59% in 2012 to 69.46% in 2017. With the situation of global economy, gross margin will be in decreasing trend in the following five years.
The type of BCG Vaccine includes Immune BCG and Therapy BCG. The proportion of Therapy BCG in 2016 is about 92.73%.
BCG Vaccine is widely used in Hospitals and Clinics. The most proportion of BCG Vaccine is sold in Hospitals and the market share in 2016 is about 74.14%, and the Hospitals have upstream trend.
North America is the largest supplier of BCG Vaccine, with a production market share nearly 32.58% in 2016. Europe is the second largest supplier of BCG Vaccine Media, enjoying production market share nearly 29.74% in 2016.
North America region is the largest consumption of BCG Vaccine, with a sales revenue market share nearly 36.40% in 2016. Europe is the second largest consumer of BCG Vaccine, enjoying sales revenue market share about 32.43% in 2016.
Market competition is not intense. Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, GSBPL are the leaders of the industry, and they have been formed in the monopoly position in the industry.
The worldwide market for BCG Vaccine is expected to grow at a CAGR of roughly 5.5% over the next five years, will reach 410 million US$ in 2024, from 300 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the BCG Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Merck
- Sanofi Pasteur
- Japan BCG Lab
- China National Biotec
- Serum Institute of India
- Intervax
- GSBPL
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Immune BCG
- Therapy BCG
Market Segment by Applications, can be divided into
- Hospitals
- Clinics
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe BCG Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of BCG Vaccine, with price, sales, revenue and global market share of BCG Vaccine in 2017 and 2018.
Chapter 3, the BCG Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the BCG Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, BCG Vaccine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe BCG Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.